At a glance
ClinicalIndex Comparison Record- ✓Histologically proven stage II, III, or IV low-grade non-Hodgkin's lymphoma
- ✓Unlikely to respond to existing therapy or no established therapy exists
- ✓Age 18 and over
- ✓Karnofsky performance status 60-100%
- ✕History of renal conditions that contraindicate high dosages of sodium
- ✕Hypertension
- ✕History of congestive heart failure
- ✕History of cardiovascular conditions that contraindicate high dosages of sodium
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma Low Grade
In Brief
A Phase 2 clinical trial evaluating Antineoplaston therapy (Atengenal + Astugenal) for Low-Grade Lymphoma. Completed, enrolled 31 participants across 1 site.
Detailed Summary
Current therapies for Low-grade Non-Hodgkin's Lymphoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Low-grade Non-Hodgkin's Lymphoma. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Low-grade Non-Hodgkin's Lymphoma.
Study Details
Timeline
Interventions
Patients with Low-grade non-Hodgkin's lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.